viewGemphire Therapeutics Inc

Gemphire Therapeutics shares soar on optimistic Phase 2b trial results for gemcabene

Key endpoints were met in the trial, which analyzed how well the drug treats severe hypertriglyceridemia

Shares of the clinical-stage biopharma more than doubled in pre-market trade

Shares of Gemphire Therapeutics Inc (NASDAQ:GEMP) rocketed in pre-market trade Friday after the clinical-stage biopharmaceutical group reported rosy results from a Phase 2b trial assessing how well its drug gemcabene treats patients with severe hypertriglyceridemia.

In the trial, called INDIGO-1, patients who took 600mg of gemcabene reported far lower triglycerides – as at the median level, their triglyerides fell by 47% compared to a 27% reduction for patients who took a placebo.

Severe hypertriglyceridemia is a condition in which patients have triglycerides, a type of fat, present in the bloodstream at a level greater than 500mg/dL. These high levels are associated with an increase in both the risk for cardiovascular disease and acute pancreatitis.

Prior to the opening bell, Gemphire shares jumped 146% to US$12.89 in response to the good news.

Key endpoints reached

Primary and secondary endpoints were both met in the trial, which lasted twelve weeks and phase 3 trials are expected to follow.

“We are pleased to reach this milestone of meeting both primary and multiple secondary endpoints and look forward to advancing gemcabene into Phase 3 trials,” said Dr Steven Gullans, Gemphire’s chief executive.

“There are approximately 3.5mln patients with severe hypertriglyceridemia in the US who are in need of lowering their triglyceride levels below 500mg/dL to reduce their risk of developing acute pancreatitis,” he added

Another positive to come out of the study was that gemcabene appeared safe and well-tolerated on its own or as an additional therapy to statins.

The INDIGO-1 results also support the company’s plan to use gemcabene as a liver drug to treat non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). A pair of phase 2a proof of concept trials assessing gemcabene’s potential to fight NAFLD and NASH are under way, with data expected later this year and early in 2019.

Contact Ellen Kelleher at [email protected]

Quick facts: Gemphire Therapeutics Inc

Price: - -

Market: NASDAQ
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Emperor Energy welcomes strong support for SPP as it progresses with Judith...

Emperor Energy Ltd's (ASX:EMP) Carl Dumbrell joins Proactive's Andrew Scott soon after receiving firm commitments to raise $656,000 through its share purchase plan (SPP) – attracting more than double the minimum $300,000 target. Net proceeds will go towards strengthening the company’s balance...

5 hours, 45 minutes ago

2 min read